ABSTRACT
INTRODUCTION
The last 3 years have witnessed tremendous advances in the treatment of castrationresistant prostate cancer (CRPC), a disease from which approximately 30,000 men die abiraterone acetate (Zytiga Ò , Janssen Biotech, Inc, Horsham, PA, USA), a first-in-class, highly potent and tolerable androgen biosynthesis inhibitor, which elicited a median 4-month survival benefit in docetaxel-refractory patients [4, 5] . 2012 showcased the survival-improving abilities of both enzalutamide (formerly MDV3100), an agent engineered to block both the binding of androgens to the androgen receptor (AR) and nuclear transport of AR, and a novel bone metastasis-homing radiotherapeutic agent, radium-223 chloride (formerly Alpharadin Ò , Algeta US, LLC, Cambridge, MA, USA and Bayer, Pittsburgh, PA, USA) [6] [7] [8] . Abiraterone acetate moved to the pre-chemotherapy setting after demonstrating improvements in progressionfree survival (PFS) and overall survival (OS) when compared to prednisone/placebo [9] .
Finally, the introduction of a novel boneprotective agent, denosumab, which delays time to skeletal metastasis and skeletal-related events in the 'pre-abiraterone/enzalutamide' era, has complemented these survivalenhancing cytotoxic and hormonal therapies [10, 11] .
Prostate cancer is a very heterogeneous disease, which can range from slowly growing, indolent disease that would never induce death, to aggressive variants that necessitate immediate initiation of systemic therapy to control disease progression and symptoms. Multiple lines of evidence have shown that androgens drive the growth and survival of prostate cancer cells [12, 13] . The pioneering work of Charles Huggins and colleagues [14] in the 1940s formed the cornerstone of the initial treatment for advanced prostate cancer, which is directed at ablating androgen synthesis pathways either by medical or surgical castration. While initially immensely effective in most patients, within 2-3 years, almost all patients with metastatic disease develop insensitivity to first-line androgen deprivation therapy (ADT) despite castrate levels of serum testosterone, a disease state now referred to as CRPC or, in the past, hormone-refractory or androgen-independent disease [15, 16] .
While the expanding treatment armamentarium is encouraging, CRPC remains lethal and the individual survival benefits of even the newest agents remain modest at 2-5 months [2-6, 8, 17] . Further, the taxanes have cumulative toxicities, and the immunotherapeutic sipuleucel-T is labor intensive, and elicits few tangible prostatespecific antigen (PSA) or radiologic responses to decrease patient anxiety and control symptoms [3, 17] . Moreover, all of the new agents are costly. Administration of second-line hormonal therapies is often pursued prior to chemotherapy given their enhanced tolerability and with the rationale of targeting the theoretical persistent dependence on AR signaling, even after castration resistance has been proven clinically. The PSA responses achieved by the adrenal steroid biosynthesis inhibitor, ketoconazole, and second-line antiandrogens, like nilutamide, provide evidence for this continued reliance on androgens in CRPC [18] [19] [20] [21] . The more substantial declines in PSA and improvements in survival with abiraterone acetate and enzalutamide validate this principle.
This review will focus on abiraterone acetate, which is a selective inhibitor of cytochrome P450 17 (CYP17) a-hydroxylase and cytochrome 17, 20 (C 17,20 )-lyase, enzymes, which are critical to androgen synthesis (Fig. 1) . Abiraterone acetate elicits significant antitumor activity in CRPC. It induces PSA declines of C50% in 29-62% of patients, achieves OS benefits in both docetaxelrefractory and chemotherapy-naïve patients, delays and reduces skeletal-related events, and palliates pain [4, 9] (Table 1 ). This multi-faceted efficacy, along with an excellent safety and tolerability profile compared to chemotherapy, positions abiraterone acetate as an agent that enhances patient outcomes and quality of life in the pre-chemotherapy setting, and it may be incorporated as part of novel treatment approaches in earlier disease states. We will detail the development of abiraterone acetate, consider its placement in the expanding CRPC treatment armamentarium, and discuss future strategies to enhance its effectiveness.
CASTRATION-RESISTANT PROSTATE CANCER
Phase III trials completed in the 1990s reported a median OS of 16-18 months from the start of docetaxel in CRPC. In contrast, contemporary phase III trials of androgen axis inhibitors, such as abiraterone acetate and enzalutamide, given after docetaxel therapy have reported a median survival of 15-18 months [4, 6] . This improvement in median survival is related to both a shift toward earlier initiation of treatment and a real improvement in survival elicited by these new agents. The drivers behind the progression to CRPC are multifactorial but can be attributed to persistence of androgens from non-gonadal sources and intratumoral AR signaling. Rarer transformation to true androgen axis independence can also occur [22] . In the eugonadal state, the testes synthesize 80% of the body's testosterone, but another 20% is produced by the adrenal glands, and in CRPC, the tumor itself can produce intracrine androgens [23] . Tissue studies in healthy volunteers have demonstrated that despite [31] .
The AR regulates PSA expression, and an elevated PSA level is usually the first manifestation of CRPC. An elevated PSA may reflect renewed AR activation or ongoing transcription of androgen-AR-regulated genes, which may primarily stimulate or co-stimulate cancer growth [32] [33] [34] . This sign of persistent intratumoral AR signaling in CRPC suggests potential sensitivity to more intensive androgen deprivation, which has been evidenced by the \56% PSA response rates with older-generation, second-line hormonal agents, such as ketoconazole and the AR antagonists, bicalutamide (daily dose of 50-200 mg), flutamide, and nilutamide [18-20, 35, 36] . The persistence of serum PSA and the responses seen with older, secondary hormonal blockade, combined with a desire to develop less toxic and more selective agents than existing chemotherapeutics has driven the development of the latest generation of AR and androgen biosynthesis inhibitors. These agents include the ligand synthesis inhibitors, abiraterone acetate and orteronel (TAK-700), the receptor signaling inhibitors, enzalutamide and ARN509, as well as the combined receptor and androgen synthesis inhibitor, galeterone (TOK-001).
CLINICAL INVESTIGATION OF ABIRATERONE ACETATE IN CRPC
Abiraterone acetate is the prodrug of abiraterone. It acts through irreversible CYP17 inhibition, but is more targeted and potent than the older generation, non-specific CYP inhibitor, ketoconazole. Its superior efficacy and tolerability reflect this greater selectivity against CYP17, making it significantly more potent than ketoconazole [23, 37] . Abiraterone acetate's inhibition of CYP17 a-hydroxylase and C 17,20 -lyase triggers a cascade of predictable endocrinologic changes (Fig. 1 production. There is potential for resultant mineralocorticoid excess (ME), which is a possible dose-limiting toxicity of abiraterone acetate in some patients. However, the incidence of ME is generally abrogated by concomitant administration of prednisone (or dexamethasone) or aldosterone antagonists, such as eplerenone or even spironolactone [38] . The most common symptoms of ME observed with abiraterone acetate administration are hypokalemia, hypertension, and edema, and were seen in 17, 10-22, and 28-31% of patients, respectively, in the phase III studies [4, 9] . Abiraterone acetate was initially studied in the chemotherapy-naïve CRPC setting [32, [39] [40] [41] . In the first phase I/II trial, de Bono and Attard evaluated abiraterone as monotherapy without concomitant steroids in 54 patients [32] . Continued administration of a luteinizing hormone-releasing hormone (LHRH) agonist was mandated to prevent any compensatory luteinizing hormone (LH) surge and testosterone production that might overwhelm abiraterone acetate's CYP17 blockade [32, 42] . While up to 2,000 mg per day was found to be tolerable, a plateau in pharmacodynamic effect advocated for 1,000 mg as the recommended monotherapy dose [39] . Notably, abiraterone also induced near-undetectable levels of circulating androgens, such as serum testosterone, DHEA-sulfate, and DHT, but increased levels of mineralocorticoids, such as deoxycorticosterone and aldosterone. In fact, the development of exquisitely sensitive assays, such as liquid chromatography tandem mass spectrometry, was required to measure such low levels of androgen [39] . Despite the increased levels of mineralocorticoids, no symptoms of ME were reported. Of the 42 patients enrolled in this phase II trial who were treated with abiraterone acetate 1,000 mg daily, 67%
achieved a PSA decline of C50%. all responses were ongoing at the time of publication of the results. Higher pre-treatment androgen and estradiol levels were associated with an increased probability of PSA response and prolonged TTPP [32] . These findings may indicate that these serum hormone levels are predictive biomarkers that could optimize the selection of patients who would be most likely to benefit from abiraterone acetate therapy. were observed not only in patients who had not responded (33%) to ketoconazole, but also in those who had initially responded but eventually progressed on ketoconazole (46%) [41] . These latter results indicate a lack of crossresistance between the two agents.
Confirming the preliminary efficacy observed in the phase I studies, a subsequent phase II trial evaluated abiraterone acetate plus prednisone in 33 patients with progressive, metastatic, CRPC who were both chemotherapy-and ketoconazole-naïve [40] .
The great majority (79%) of patients had a decline in PSA levels of C50%. Disease control was remarkably durable for this population, with a median time to PSA progression of 16.3 months. Interestingly, discordant bone scans occurred in nearly half (11/23) of the patients who were thought to be responding to abiraterone acetate by PSA criteria [40] . These discordant responses were later confirmed to be flare phenomena, since the lesions improved on subsequent scans. Flare phenomenon occurs when, despite other signs of clinical response such as PSA decline, bone lesions appear more intense on bone scan. The 'worsening' of the lesion actually reflects treatment response, but may be misinterpreted as disease progression by the reviewer [40] . The requirement by Ryan and colleagues for a confirmatory scan highlights the potential for this phenomenon to occur with abiraterone acetate treatment. It may occur in up to 50% of cases, which emphasizes the importance of confirmatory scans prior to therapy discontinuation with this agent [40] .
Evolving imaging techniques with novel tracers and the incorporation of serum and urine markers of bone turnover, such as bonespecific alkaline phosphatase, may further distinguish flare effects due to treatment response from those of disease progression.
The 6.6 months, respectively; P\0.001), PFS (5.6 vs. 3.6 months, respectively; P\0.001), and PSA response rate (29% vs. 6%, respectively; P\0.001). The final analysis of the study occurred before unblinding and subsequent patient crossover from placebo to abiraterone acetate [5] . After 775 of the pre-specified 799 death events and a median 20.2 months of follow-up, median OS was 15.8 months versus 11.2 months for the abiraterone arm compared with the placebo arm, respectively (HR 0.74, 95% CI 0.64-0.86; P\0.0001). Median time to PSA progression was 8.5 months, median radiologic PFS was 5.6 months, and 29.5% of patients had a PSA response on the abiraterone acetate arm; all were statistically significantly increased compared with the corresponding results in the placebo arm, and were similar to the initial efficacy analysis [5] .
The most common toxicities attributed to abiraterone acetate in the phase III, postdocetaxel study were related to testosterone depletion and ME, such as fluid retention, hypertension, and hypokalemia. The most common grade 3-4 events occurred with similar frequency in both cohorts: fatigue (9-10%), anemia (8%), back pain (7% vs. 10%), and bone pain (6% vs. 8%) [5] . No new safety concerns were identified in the phase III study. Importantly, fewer patients discontinued treatment because of toxicity in the abiraterone acetate group compared to the control group (13% vs. 18%, respectively) [5] .
The phase III, post-docetaxel abiraterone acetate trial was also notable for its integrated correlative assessments of quality of life, fatigue, and pain. These factors are important considerations, as patients with CRPC can range from being asymptomatic to having significant debilitating bony pain or multifactorial fatigue related to anemia, past anti-cancer treatment, or cancer progression.
Sternberg and colleagues incorporated into the phase III abiraterone study 'The Brief Fatigue Inventory', a validated fatigue assessment tool as an outcome measure [47] . In patients who reported clinically significant fatigue at study initiation, abiraterone acetate achieved clinically meaningful benefits compared to prednisone alone. It elicited significant reductions in intensity of fatigue, improved fatigue interference, and faster reduction in fatigue intensity [47] . To assess whether pain and skeletal-related events were reduced with abiraterone acetate, Logothetis and colleagues [48] issued Based on a 4-month survival benefit, the FDA granted approval of abiraterone acetate in April 2011 [4] . Given the need to improve tolerability of therapeutic agents and preference to avoid chemotherapy, abiraterone acetate's outcomes in chemotherapy-naïve patients were highly anticipated. Ryan and colleagues executed a phase III study in asymptomatic or only mildly symptomatic patients with progressive, chemotherapy-naïve metastatic CRPC disease [9] . This multicenter, international trial randomized 1,088 patients in a 1:1 fashion to receive either abiraterone acetate 1,000 mg daily in combination with oral prednisone 5 mg twice daily (n = 546) or oral placebo with prednisone 5 mg twice daily (n = 542). The coprimary endpoints were radiographic PFS and personal communication). The frequency of treatment discontinuation due to drug toxicity was similar in the two arms. The majority halted study treatment for progressive disease, while only 7% were discontinued due to toxicity in the abiraterone acetate arm, and 5% in the placebo arm [52] . Abiraterone acetate induced a higher rate of all grade fatigue (39%), arthralgias (28%), peripheral edema (28%), and hepatotoxicity (11-12%; \1% grade 3 or more) than prednisone [9] . As expected, other side effects related to ME, such as hypertension (22%) and hypokalemia (17%), were more common with abiraterone acetate than with prednisone; most were low grade. Hepatotoxicity generally occurred within the first 3 months of treatment and did not contribute to any deaths. Non-hypertensive cardiac events, of which there was a slight increase in the abiraterone acetate arm compared with the prednisone arm (19% vs. 16%, respectively; grade 3 or 4: 6% vs. 3%, respectively), tended to have a later onset ([3 months). These incidents included myocardial infarction, heart failure, and arrhythmias. Finally, as per the FDA notice, adrenal insufficiency was observed in 0.5% of patients on abiraterone acetate vs. 0.2% of patients on placebo [53] .
In summary, clinicians should be vigilant of the rare but real possibility of developing adrenal insufficiency with abiraterone acetate treatment, and the more common and easily treatable symptoms of ME. The long-term toxicities of steroid use, which are especially germane in a longer-living, chemotherapynaïve population, are also an important consideration. While prednisone 5 mg twice daily is the standard regimen used with abiraterone acetate and studied in the phase III setting, de Bono and colleagues initially favored dexamethasone 0.5 mg once daily due to its long half-life and lack of mineralocortical effects, and used it with satisfactory results [32] . There has been no investigation into which patients actually need steroids and at what dosage to prevent ME. Studies are ongoing to determine whether lower doses of steroid, or administration of steroids or an aldosterone antagonist at first signs of toxicity achieve similar effectiveness while optimizing safety and quality of life. Likewise, the need for concurrent GnRH axis inhibition to prevent a potential LH surge is being investigated; LH surge was observed in two of three non-castrate males given abiraterone, although it is not known whether this effect would be observed in older men with a history of long-term castration [42] .
Predictive Biomarkers and Pharmacodynamic Effects on Tissue
In addition to evaluating their effects on serum androgen and steroid levels, several investigators have attempted to look at the pharmacodynamic consequences of drugs in tumor tissue in order to better elucidate mechanisms of drug response and patterns of resistance, and to identify predictive signatures.
In an informative translational study of [54] .
The evaluation of nuclear AR and cytoplasmic CYP17 expression in this work unveiled a potential predictive signature for abiraterone acetate response [54] . AR expression by IHC was frequently higher at baseline than on treatment, while pre-treatment CYP17 expression was more heterogeneous.
Homogenous intense expression of nuclear AR in combination with C10% CYP17 tumor expression correlated with a longer time to treatment discontinuation ([4 months, P\0.001) [54] . In the cohort of 25 patients whose tumors met these criteria, only one patient had primary drug-resistant disease.
Conversely, only two patients whose tumor did not have this expression signature had a long-term response. One patient whose tumor lacked one or both of these findings had primary resistant disease (n = 10), indicating that patients without this molecular profile may not benefit from abiraterone acetate [54] . Higher pre-treatment CYP17 tumor expression also correlated with increased testosterone expression in the marrow aspirate, suggesting that these tumors are capable of intratumoral androgen synthesis, which may drive their disease resistance [54] . This work establishes the feasibility and potential value of sampling bone metastasis to explore mechanisms of resistance and to demonstrate that drugs are achieving their on-target effects. It further substantiates that persistent androgen signaling in CRPC tumors is functionally significant and confirms that abiraterone acetate effectively depletes testosterone in blood and bone marrow aspirates. This study validated Attard and colleagues' findings [39] that abiraterone acetate reduced plasma testosterone and DHT levels to undetectable levels, but was the first to prospectively establish that it also reduced marrow aspirate testosterone and DHT concentrations to lessthan-picogram-per-milliliter amounts, and that the levels remained suppressed at progression.
Men with localized but high-risk prostate cancer have suboptimal cure rates with prostatectomy [55] . Neoadjuvant trials of agents, such as abiraterone acetate, that can achieve intense androgen deprivation are a logical approach to improve outcomes in these men and permit pharmacodynamic investigation of the mechanisms of response and resistance. Taplin and colleagues executed the first randomized, neoadjuvant study investigating abiraterone acetate's pharmacodynamic effects in high-risk patients fit for prostatectomy [56] . In this multiinstitutional, phase II study, patients were initially randomized to leuprolide or leuprolide/abiraterone acetate/prednisone (5 mg daily) for 3 months (Fig. 2) [56] . The primary endpoint of the trial was the evaluation of prostate testosterone and DHT levels after 3 months of therapy. After the first 3 months of therapy, all patients were treated with an additional 3 months of leuprolide/ abiraterone acetate/prednisone (5 mg daily).
Thus, one cohort received 6 months of abiraterone acetate and the other group received 3 months of abiraterone acetate, but all patients received 6 months of ADT in total [56] . All participants had prostatectomy after 6 months of ADT. Eligibility targeted high-risk patients and required that patients had positive biopsies in three or more cores, Gleason score C7 (4 ? 3), stage T3 disease, PSA C20 ng/mL, or a PSA velocity of [2 ng/ mL/year [56] . Fifty-eight patients were accrued over 18 months. Secondary endpoints included pathologic staging at prostatectomy, PSA response, and assessment of androgen receptor signaling. Publication of the results of this work is pending, and only data presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting is described here [56] .
Longer (6-month) compared with shorter (3-month) abiraterone acetate administration achieved a greater percentage of pathologic complete response (CR) (10% vs. 4%, respectively), near pathologic CR (24% vs. 11%, respectively), and any disease shrinkage, as assessed by a composite endpoint of true pathologic CR plus near CR (15% vs. 34%, respectively) [56] . The primary endpoint was to induce a significant reduction in prostate tumor androgen levels (DHT and DHEA) at the 12-week mark and was realized with the combination therapy compared to leuprolide alone (P\0.0001). In the group who started abiraterone acetate after 12 weeks of leuprolide monotherapy, the addition of abiraterone acetate induced a statistically significant decrease in DHT and DHEA levels at 24 weeks compared to their pre-abiraterone acetate baseline at 12 weeks (P = 0.0004) [56] . Similar decreases were seen with Fig. 2 Randomized, phase II neoadjuvant study of abiraterone acetate, leuprolide, and prednisone in newly diagnosed intermediate and high-risk patients with prostate cancer undergoing radical prostatectomy (N = 58). AA abiraterone acetate, AR androgen receptor, CaP prostate cancer, LHRHa leuprolide acetate, Pred prednisone, PSA prostate-specific antigen, qd once daily, R randomize androstenedione and, to a lesser degree, with testosterone. As expected, given the inhibition of CYP17 a-hydroxylase conversion of pregnenolone and progesterone to their 17-a hydroxy derivatives, pregnenolone and progesterone levels were higher in prostate tissue from abiraterone acetate-treated patients as compared to the corresponding levels from patients in the leuprolide monotherapy arm at 12 weeks [56] .
The safety of neoadjuvant abiraterone acetate administration is paramount given that patients are generally asymptomatic with excellent quality of life. No new safety signals were identified during this study and the toxicity profile was consistent with past phase III data in the chemotherapy-refractory setting [4, 56] . Grade 3 liver function abnormalities did not increase significantly with the longer duration of dosing: 7.1% vs. 10% with 12-and 24-week dosing of abiraterone acetate, respectively [56] . Past trials of ADT with an LHRH agonist administered neoadjuvant to prostatectomy did not alter the PSA relapse rate and this approach has been abandoned from clinical practice [57, 58] . The current availability of more effective ADT has renewed interest in the analysis of combined systemic androgen deprivation with surgery to increase cure rates in patients at high risk of recurrence. At the Dana-Farber Cancer
Institute in the US, subsequent neoadjuvant trials have been completed or are planned, evaluating intense ADT neoadjuvant to prostatectomy, assessing various compounds, including combinations of abiraterone acetate, enzalutamide, dutasteride, and ARN509. We hope to determine the optimal combination and duration of neoadjuvant ADT that will lead to a randomized, phase III trial in high-risk patients.
Resistance Mechanisms in the AR Pathway
As with all available therapies, eventual resistance to abiraterone acetate occurs. [69] .
The survival advantage of sipuleucel-T has considerably challenged the dogma that prostate cancer is not an immunotherapysensitive tumor. Nesslinger and colleagues [70] demonstrated that hormone therapy and radiation could elicit antigen-specific immune responses in the form of development of autoantibodies to tumor-associated antigens. whether the concomitant steroids given as standard to prevent abiraterone acetateinduced ME will dampen the immune response to sipuleucel-T. Data presented at ASCO 2013 suggested that steroids did not diminish the immune system response to sipuleucel-T, but this conclusion awaits validation [72] .
Another mechanism of resistance may be upregulation of programmed death 1 ligand 
CONCLUSION
The last several years have engendered tremendous optimism for the treatment of advanced prostate cancer. Patients now have access to more than five therapies that prolong survival, with several more on the horizon. These much-needed advances in survival are perhaps best demonstrated by the placebo arm of the chemotherapy-naïve, phase III abiraterone acetate trial, where patients had a median OS of 27 months, an increase from 18 months in the docetaxel era [9, 17] . While both cohorts of patients received steroids, which have some activity, and there has also likely been an inherent shift to initiating therapy earlier, this approximately 10-month improvement in median OS is more likely the consequence of the increased availability and sequential use of multiple survival-improving therapies, which patients on these trials had access to after unblinding [9] . Tolerable, effective agents, such as abiraterone acetate, are critical for improving survival while maintaining quality of life. Abiraterone acetate remains a valuable option post-chemotherapy, but the FDA's expanded indication to the chemotherapy-naïve setting addresses a critical unmet need, and in the future, abiraterone acetate is likely to be used predominantly prior to chemotherapy. Abiraterone acetate delivers clinically meaningful advantages in its oral administration, favorable tolerability profile, and high efficacy. Further optimization of its use is being investigated with the use of lower doses or no concurrent steroids, and without concomitant gonadal suppression.
In addition to abiraterone acetate's clinical benefits, its development is noteworthy for having confirmed the clinical importance of intratumoral androgen synthesis, which may promote therapeutic resistance, and also for validating the principle that AR signaling continues to drive disease progression after the development of castration resistance [4, 9, 25] .
Progress will require the identification of predictive biomarkers and the development of combination therapies that will enhance abiraterone acetate's efficacy and thwart resistance pathways. Future study will address whether its use concurrently or in sequence with other highly effective agents, such as enzalutamide or sipuleucel-T, will result in synergistic effects, and whether, as is currently done with leuprolide acetate, abiraterone acetate should be continued past progression. 
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